Active substance
Ceftriaxone
- SFDA 75
- US FDA 43
- Health Canada 13
- US price lines 6
- NHS prices 1
- WHO EML 2
- Safety 15
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CEFAJECT 1 g IM | 1 g | Powder for solution for injection/infusion · Intramuscular use | 1 Vial | SAR 40.95 | Generic · Prescription | Abbott Laboratories GmbH | Valid |
| CEFAJECT 1 g IV | 1 g | Powder for solution for injection/infusion · Intravenous use | 1 Vial | SAR 40.95 | Generic · Prescription | Abbott Laboratories GmbH | Valid |
| CEFAJECT 500 mg IM | 500 mg | Powder for solution for injection/infusion · Intramuscular use | 1 Vial | SAR 23.80 | Generic · Prescription | Abbott Laboratories GmbH | Valid |
| CEFAJECT 500 mg IV | 500 mg | Powder for solution for injection/infusion · Intravenous use | 1 Vial | SAR 23.80 | Generic · Prescription | Abbott Laboratories GmbH | Valid |
| CEFAXON 1GM I.M+5 ML LIDOCAINE VIAL | 1 g | Solution · Intramuscular use | 1 Vial | SAR 48.05 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| CEFAXON 1GM I.V VIAL | 1 g | Solution for injection · Intravenous use | 1 Vial | SAR 48.05 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| CEFAXON 500 MG I.M+5 ML LIDOCAINE VIAL | 500 mg | Solution · Intramuscular use | 1 Vial | SAR 29.30 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| CEFAXON 500 MG I.V VIAL | 500 mg | Solution · Intravenous use | 1 Vial | SAR 14.85 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Ceftriaxone Amarox | 1 g | Powder and solvent for solution for injection · Intramuscular and intravenous use | 1 Vial | SAR 21.00 | Generic · Prescription | Saudi Amarox | Valid |
| Ceftriaxone Venus | 1 g | Powder for solution for injection/infusion · Intramuscular and intravenous use | 1 Vial | SAR 19.15 | Generic · Prescription | VENUS REMEDIES LIMITED | Valid |
| ENOXIRT 0.25 g I.V. VIAL | 250 mg | powder for solution for injection · Intravenous use | 10 Vial | SAR 135.00 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ENOXIRT 0.25GM I.M. VIAL + SOLVENT | 250 mg | powder for solution for injection · Intramuscular use | 1 Vial | SAR 11.30 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ENOXIRT 0.25GM I.V. VIAL + SOLVENT | 250 mg | powder for solution for injection · Intravenous use | 1 Vial | SAR 11.30 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ENOXIRT 1 g I.V. VIAL | 1 g | powder for solution for injection · Intravenous use | 10 Vial | SAR 413.25 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ENOXIRT 1GM I.M. VIAL + SOLVENT | 1 g | powder for solution for injection · Intramuscular use | 1 Vial | SAR 45.30 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ENOXIRT 1GM I.V. VIAL + SOLVENT | 1 g | powder for solution for injection · Intravenous use | 1 Vial | SAR 45.30 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ENOXIRT 500 mg I.V. Vial | 500 mg | powder for solution for injection · Intravenous use | 10 Vial | SAR 239.00 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ENOXIRT 500MG I.M. VIAL + SOLVENT | 500 mg | powder for solution for injection · Intramuscular use | 1 Vial | SAR 22.65 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| ENOXIRT 500MG I.V. VIAL + SOLVENT | 500 mg | powder for solution for injection · Intravenous use | 1 Vial | SAR 22.65 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| MEGION 0.5GM I.V INJECTION | 500 mg | Solution for injection · Intravenous use | 1 Vial | SAR 20.10 | Generic · Prescription | SANDOZ | Valid |
| MEGION 1GM I.V - I.M INJECTION | 1 g | Solution for injection · Intramuscular use | 1 Vial | SAR 21.00 | Generic · Prescription | SANDOZ | Valid |
| MESPORIN 1000 I.M. | 1000 mg | Powder and solvent for suspension for injection · Intramuscular use | 1 Vial | SAR 30.55 | Generic · Prescription | Acino AG | Valid |
| MESPORIN 1000 I.V | 1 g | Powder and solvent for suspension for injection · Intravenous use | 1 Vial | SAR 30.55 | Generic · Prescription | Acino AG | Valid |
| MESPORIN 2000 I.V | 2 g | Powder and solvent for suspension for injection · Intravenous use | 1 Vial | SAR 61.10 | Generic · Prescription | Acino AG | Valid |
| MESPORIN 500 I.M. | 500 mg | Powder and solvent for suspension for injection · Intramuscular use | 1 Vial | SAR 15.25 | Generic · Prescription | Acino AG | Valid |
50 more — full table
Indications — CHI Daman Drug Formulary
ACUTE BACTERIAL PROSTATITIS; ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS); ACUTE PANCREATITIS; ACUTE PYELONEPHRITIS; ANTIBIOTIC SURGICAL PROPHYLAXIS; BACTERIAL MENINGITIS; BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL SKIN INFECTIONS - GAS GANGRENE; BACTERIAL SKIN INFECTIONS - NECROTIZING FASCIITIS; BACTERIAL SKIN INFECTIONS - SURGICAL SITE INFECTIONS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - OTHER SALMONELLA INFECTIONS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - SHIGELLA INFECTIONS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - TYPHOID AND PARATYPHOID FEVERS; BACTRIAL INFECTIONS OF THE GASTROINTESTINAL TRACT - VIBRIO CHOLERAE; BRUCELLOSIS; COMMUNITY ACQUIRED PNEUMONEA; ENDOCARDITIS; HOSPITAL AND VENTILATER ACQUIRED PNEUMONIA; INTRA-ABDOMINAL INFECTIONS; LIVER CIRRHOSIS; MUCOPURULENT CONJUCTIVITIS - GONOCOCCAL INFECTION OF THE EYE; ORCHITIS AND EPIDIDYMITIS; OSTEOMYELITIS; OTITIS MEDIA; PELVIC INFLAMMATORY DISEASE; PERITONITIS; PREVENTION AND CHEMOPROPHYLAXIS OF BACTERIAL MENINGITIS- MENINGITIS, MENINGOCOCCAL INFECTIONS PREVENTION (CHEMOPROPHYLAXIS); Pyogenic Arthritis; RECURRENT URINARY TRACT INFECTIONS (UTI); Septic Shock; SICKLE CELL DISEASE - ACS MANAGEMENT; SINUSITIS; TRAVEL RELATED INFECTIONS-TREATMENT; URETHRITIS & NONGONOCOCCAL URETHRIIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | B BRAUN | Prescription | 20 Apr 2005 |
| CEFTRIAXONE | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · intramuscular, intravenous | SANDOZ | Prescription | 9 May 2005 |
| CEFTRIAXONE | EQ 10GM BASE/VIAL | injectable · injection | SANDOZ | Prescription | 17 May 2005 |
| CEFTRIAXONE IN PLASTIC CONTAINER | EQ 20MG BASE/ML; EQ 40MG BASE/ML | injectable · injection | BAXTER HLTHCARE | Prescription | 23 Aug 2005 |
| CEFTRIAXONE | EQ 1GM BASE/VIAL | injectable · injection | APOTEX | Prescription | 12 May 2006 |
| CEFTRIAXONE | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 2GM BASE/VIAL | injectable · intramuscular, intravenous | WOCKHARDT BIO AG | Prescription | 12 Apr 2007 |
| CEFTRIAXONE | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · intramuscular, intravenous | HIKMA FARMACEUTICA | Prescription | 10 Jan 2008 |
| CEFTRIAXONE | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · intramuscular, intravenous | EPIC PHARMA LLC | Prescription | 11 Jan 2008 |
| CEFTRIAXONE | EQ 10GM BASE/VIAL | injectable · injection | ACS DOBFAR | Prescription | 24 Jul 2008 |
| CEFTRIAXONE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | ACS DOBFAR | Prescription | 24 Jul 2008 |
| CEFTRIAXONE | EQ 100GM BASE/VIAL | injectable · injection | SAMSON MEDCL | Prescription | 25 Apr 2014 |
| CEFTRIAXONE | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · intramuscular, intravenous | QILU ANTIBIOTICS | Prescription | 29 Jun 2016 |
| CEFTRIAXONE SODIUM | EQ 10GM BASE/VIAL | injectable · injection | ANDA REPOSITORY | Prescription | 20 Jan 2017 |
| CEFTRIAXONE SODIUM | EQ 10GM BASE/VIAL | injectable · injection | HIKMA | Prescription | 4 Oct 2017 |
| CEFTRIAXONE | EQ 10GM BASE/VIAL | injectable · injection | QILU ANTIBIOTICS | Prescription | 17 Oct 2018 |
| ROCEPHIN | EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · intramuscular, intravenous | HOFFMANN LA ROCHE | Discontinued | 21 Dec 1984 |
| ROCEPHIN | EQ 10GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | HOFFMANN LA ROCHE | Discontinued | 21 Dec 1984 |
| ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER | EQ 10MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 20MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 40MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | HOFFMANN LA ROCHE | Discontinued | 11 Feb 1987 |
| ROCEPHIN | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | HOFFMANN LA ROCHE | Discontinued | 30 Apr 1987 |
| ROCEPHIN | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | HOFFMANN LA ROCHE | Discontinued | 13 Aug 1993 |
| CEFTRIAXONE | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · intramuscular, intravenous | LUPIN | Discontinued | 30 Sep 2003 |
| CEFTRIAXONE | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | SANDOZ INC | Discontinued | 3 May 2005 |
| CEFTRIAXONE | EQ 250MG BASE/VIAL; EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · intramuscular, intravenous | HOSPIRA INC | Discontinued | 2 Aug 2005 |
| CEFTRIAXONE | EQ 1GM BASE/VIAL; EQ 2GM BASE/VIAL | injectable · injection | HOSPIRA INC | Discontinued | 2 Aug 2005 |
| CEFTRIAXONE | EQ 10GM BASE/VIAL | injectable · injection | HOSPIRA INC | Discontinued | 2 Aug 2005 |
18 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CEFTRIAXONE FOR INJECTION | 02289695 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | FRESENIUS KABI CANADA LTD |
| CEFTRIAXONE FOR INJECTION | 02289709 | 2 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| CEFTRIAXONE FOR INJECTION | 02409968 | 100 G / BAG | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| CEFTRIAXONE INJECTION, USP | 02499711 | 1000 MG / 50 ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
| CEFTRIAXONE INJECTION, USP | 02499738 | 2000 MG / 50 ML | SOLUTION · INTRAVENOUS | BAXTER CORPORATION |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 02292262 | 250 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | SANDOZ CANADA INCORPORATED |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 02292270 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 02292289 | 2 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | SANDOZ CANADA INCORPORATED |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 02292297 | 10 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 02325594 | 250 MG / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | STERIMAX INC |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 02325616 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | STERIMAX INC |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 02325624 | 2 G / VIAL | POWDER FOR SOLUTION · INTRAMUSCULAR; INTRAVENOUS | STERIMAX INC |
| CEFTRIAXONE SODIUM FOR INJECTION BP | 02325632 | 10 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CEFTRIAXONE 1 GM VIAL | $1.44341 | per EA | 23 Sep 2026 |
| US NADAC | CEFTRIAXONE 1 GM VIAL | $1.17324 | per EA | 23 Sep 2026 |
| US NADAC | CEFTRIAXONE 2 GM VIAL | $2.833 | per EA | 23 Sep 2026 |
| US NADAC | CEFTRIAXONE 250 MG VIAL | $0.8622 | per EA | 18 Feb 2026 |
| US NADAC | CEFTRIAXONE 500 MG VIAL | $1.84224 | per EA | 23 Sep 2026 |
| US NADAC | CEFTRIAXONE 500 MG VIAL | $1.31395 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Ceftriaxone 1g powder for solution for injection vials | £9.58 | 1 vial | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.2. Watch group antibiotics · core
First choice: Other specified pneumonia (Hospital-acquired pneumonia); First choice: Acute pyelonephritis (severe); First choice: Paratyphoid fever; First choice: Typhoid fever; First choice: Endophthalmitis; First choice: Bacterial pneumonia (Community-acquired pneumonia - severe); First choice: Bacterial pneumonia (Community-acquired pneumonia - severe) [children]; First choice: Bacterial meningitis; First choice: Inflammatory or other diseases of prostate (severe) (co-prescribed with amikacin); First choice: Gonococcal infection (co-prescribed with azithromycin); First choice: Necrotising fasciitis (co-prescribed with metronidazole); First choice: Peritoneal abscess (mild-moderate) (co-prescribed with metronidazole); First choice: Peritoneal abscess (severe) (co-prescribed with metronidazole); First choice: Peritonitis (mild-moderate) (co-prescribed with metronidazole); First choice: Peritonitis (severe) (co-prescribed with metronidazole); Second choice: Acute pyelonephritis (mild to moderate); Second choice: Bacterial infection of joint; Second choice: Sepsis without septic shock; Second choice: Infectious gastroenteritis or colitis without specification of infectious agent; Second choice: Inflammatory or other diseases of prostate (mild to moderate); Second choice: Osteomyelitis or osteitis
Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) (EML) | Parenteral > Locoregional injections > Intravitreal: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) (EML) | Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) (EML); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) | Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt) (EML); 2 g in vial powder for injection (as sodium salt) | Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial (EML) | Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) (EMLc); 500 mg in vial powder for injection (as sodium salt) (EMLc); 1 g in vial powder for injection (as sodium salt) (EMLc) - 5.1.6.1. Medicines for bacterial central nervous system infections · core
First choice: Bacterial meningitis
Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 500 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt) (EML)
Safety signals and safety-related labeling changes
- EMA PRAC 11 Jul 2024 PRAC signal: Precipitation when administered with calcium-containing solutions in infants between 29 days and 1 year
Action for MAH: update of the product information: No - EMA PRAC 8 Feb 2024 PRAC signal: Precipitation when administered with calcium-containing solutions in infants between 29 days and 1 year
Action for MAH: update of the product information: No - EMA PRAC 16 Mar 2023 PRAC signal: Factor V inhibition
Action for MAH: update of the product information: No - EMA PRAC 27 Oct 2022 PRAC signal: Factor V inhibition
Action for MAH: update of the product information: No - US FDA 13 Jan 2022 CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 10 Jun 2021 PRAC signal: Hepatitis
Action for MAH: update of the product information: Yes - EMA PRAC 11 Feb 2021 PRAC signal: Hepatitis
Action for MAH: update of the product information: No - EMA PRAC 29 Oct 2020 PRAC signal: Encephalopathy
Action for MAH: update of the product information: Yes - EMA PRAC 3 Sep 2020 PRAC signal: Hepatitis
Action for MAH: update of the product information: No - EMA PRAC 17 Apr 2020 PRAC signal: Encephalopathy
Action for MAH: update of the product information: No - EMA PRAC 31 Oct 2019 PRAC signal: Encephalopathy
Action for MAH: update of the product information: No - US FDA 12 Jul 2018 ROCEPHIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 12 Jul 2018 ROCEPHIN KIT — safety-related labeling change
Labeling sections changed: Warnings and Precautions - EMA PRAC 8 Jul 2016 PRAC signal: Drug reaction with eosinophilia and systemic symptoms (DRESS)
Action for MAH: update of the product information: No - MHRA 11 Dec 2014 Ceftriaxone (rocephin): incompatible with solutions containing calcium
Updated advice for healthcare professionals not to mix or infuse ceftriaxone with solutions containing calcium.
Combinations containing Ceftriaxone
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.